Advanced search
Publication Cover
Pharmacogenomics Volume 11, 2010 - Issue 3
Submit an article Journal homepage
535
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenomics in the Treatment of Inflammatory Bowel Disease

Melissa A Smith1 Department of Gastroenterology, 1st Floor, College House, St Thomas‘ Hospital, Lambeth Palace Road, London, SE1 7EH, UK.View further author information
,
Anthony M Marinaki2 Purine Research Laboratory, Guy‘s & St Thomas‘ NHS Foundation Trust, London, UKView further author information
&
Jeremy D Sanderson1 Department of Gastroenterology, 1st Floor, College House, St Thomas‘ Hospital, Lambeth Palace Road, London, SE1 7EH, UK.Correspondence[email protected]
View further author information
Pages 421-437 | Published online: 17 Mar 2010

Bibliography

  • Lowenberg M , PeppelenboschM, HommesD: Biological therapy in the management of recent-onset Crohn‘s disease: why, when and how?Drugs66(11) , 1431–1439 (2006).
  • Hyams JS , MarkowitzJF: Can we alter the natural history of Crohn disease in children?.J. Pediatr. Gastroenterol. Nutr.40(3) , 262–272 (2005).
  • McGuckin MA , EriR, SimmsLA et al.: Intestinal barrier dysfunction in inflammatory bowel diseases.Inflamm. Bowel Dis.15(1) , 100–113 (2009).
  • Sim E , LackN, WangCJ et al.: Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.Toxicology254(3) , 170–183 (2008).
  • Azad Khan AK , NurazzamanM, TrueloveSC: The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.J. Med. Genet.20(1) , 30–36 (1983).
  • Lück H , KinzigM, JetterA, FuhrU, SörgelF: Mesalazine pharmacokinetics and NAT2 phenotype.Eur. J. Clin. Pharmacol.65(1) , 47–54 (2009).
  • Hickman D , PopeJ, PatilSD et al.: Expression of arylamine N-acetyltransferase in human intestine.Gut42(3) , 402–409 (1998).
  • Das KM , EastwoodMA, McManusJP, SircusW: The metabolism of salicylazo-sulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.Gut14(8) , 631–641 (1973).
  • Tanigawara Y , KitaT, AoyamaN et al.: N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.Biol. Pharm. Bull.25(8) , 1058–1062 (2002).
  • Gunnarsson I , KanerudL, PetterssonE, LundbergI, LindbladS, RingertzB: Predisposing factors in sulphasalazine-induced systemic lupus erythematosus.Br. J. Rheumatol.36(10) , 1089–1094 (1997).
  • Chen M , XiaB, ChenB et al.: N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.Can. J. Gastroenterol.21(3) , 155–158 (2007).
  • Rahav G , Zylber-KatzE, RachmilewitzD, LevyM: Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.Isr. J. Med. Sci.26(1) , 31–34 (1990).
  • Ohtani T , HiroiA, SakuraneM, FurukawaF: Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.Br. J. Dermatol.148(5) , 1035–1039 (2003).
  • Ricart E , TaylorWR, LoftusEV et al.: N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.Am. J. Gastroenterol.97(7) , 1763–1768 (2002).
  • Wadelius M , StjernbergE, WiholmBE, RaneA: Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.Pharmacogenetics10(1) , 35–41 (2000).
  • Ansari A , ArenasM, GreenfieldSM et al.: Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Aliment Pharmacol. Ther.28(8) , 973–983 (2008).
  • Hausmann M , PaulG, MenzelK et al.: NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis.Z. Gastroenterol.46(3) , 259–265 (2008).
  • Munkholm P , LangholzE, DavidsenM, BinderV: Frequency of glucocorticoid resistance and dependency in Crohn‘s disease.Gut35(3) , 360–362 (1994).
  • Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology121(2) , 255–260 (2001).
  • Barnes PJ , AdcockIM: Glucocorticoid resistance in inflammatory diseases.Lancet373(9678) , 1905–1917 (2009).
  • Creed TJ , ProbertCS: Review article: steroid resistance in inflammatory bowel disease – mechanisms and therapeutic strategies.Aliment Pharmacol. Ther.25(2) , 111–122 (2007).
  • Okamura N , SakaedaT, OkamuraK: Pharmacogenomics of MDR and MRP subfamilies.Personalized Medicine1(1) , 85–104 (2004).
  • Ueda K , OkamuraN, HiraiM et al.: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.J. Biol. Chem.267(34) , 24248–24252 (1992).
  • Farrell RJ , MenconiMJ, KeatesAC, KellyCP: P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.Aliment. Pharmacol. Ther.16(5) , 1021–1031 (2002).
  • Jamroziak K , RobakT: Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.Hematology9(2) , 91–105 (2004).
  • Onnie CM , FisherSA, PattniR et al.: Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case–control and meta-analysis study.Inflamm. Bowel Dis.12(4) , 263–271 (2006).
  • Urcelay E , MendozaJL, MartinMC et al.: MDR1 gene: susceptibility in Spanish Crohn‘s disease and ulcerative colitis patients.Inflamm. Bowel Dis.12(1) , 33–37 (2006).
  • Farrell RJ , MurphyA, LongA et al.: High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy.Gastroenterology118(2) , 279–288 (2000).
  • Potocnik U , FerkoljI, GlavacD, DeanM: Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis.Genes Immun.5(7) , 530–539 (2004).
  • Cucchiara S , LatianoA, PalmieriO et al.: Polymorphisms of tumor necrosis factor-α but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease.J. Pediatr. Gastroenterol. Nutr.44(2) , 171–179 (2007).
  • Markova S , NakamuraT, MakimotoH et al.: IL-1β genotype-related effect of prednisolone on IL-1β production in human peripheral blood mononuclear cells under acute inflammation.Biol. Pharm. Bull.30(8) , 1481–1487 (2007).
  • Markova S , NakamuraT, SakaedaT et al.: Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation.Drug Metab. Pharmacokinet.21(3) , 194–200 (2006).
  • Farrell RJ , KelleherD: Glucocorticoid resistance in inflammatory bowel disease.J. Endocrinol.178(3) , 339–346 (2003).
  • Adcock IM , LaneSJ: Mechanisms of steroid action and resistance in inflammation. Corticosteroid-insensitive asthma: molecular mechanisms.J. Endocrinol.178(3) , 347–355 (2003).
  • Raddatz D , MiddelP, BockemuhlM et al.: Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis.Aliment. Pharmacol. Ther.19(1) , 47–61 (2004).
  • Flood L , LöfbergR, StiernaP, WikströmAC: Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy.Inflamm. Bowel Dis.7(3) , 202–209 (2001).
  • Kam JC , SzeflerSJ, SursW, SherER, LeungDY: Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids.J. Immunol.151(7) , 3460–3466 (1993).
  • Honda M , OriiF, AyabeT et al.: Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis.Gastroenterology118(5) , 859–866 (2000).
  • Towers R , NaftaliT, GabayG, CarlebachM, KleinA, NovisB: High levels of glucocorticoid receptors in patients with active Crohn‘s disease may predict steroid resistance.Clin. Exp. Immunol.141(2) , 357–362 (2005).
  • Leung DY , HamidQ, VotteroA et al.: Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor β.J. Exp. Med.186(9) , 1567–1574 (1997).
  • Hausmann M , HerfarthH, SchölmerichJ, RoglerG: Glucocorticoid receptor isoform expression does not predict steroid treatment response in IBD.Gut56(9) , 1328–1329 (2007).
  • Brogan IJ , MurrayIA, CerilloG, NeedhamM, WhiteA, DavisJR: Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-κB: lack of effect of glucocorticoid receptor β.Mol. Cell Endocrinol.157(1–2) , 95–104 (1999).
  • Pujols L , MullolJ, PerezM et al.: Expression of the human glucocorticoid receptor α and β isoforms in human respiratory epithelial cells and their regulation by dexamethasone.Am. J. Respir. Cell Mol. Biol.24(1) , 49–57 (2001).
  • Koyano S , SaitoY, NaganoM et al.: Functional analysis of three genetic polymorphisms in the glucocorticoid receptor gene.J. Pharmacol. Exp. Ther.307(1) , 110–116 (2003).
  • De Iudicibus S , StoccoG, MartelossiS et al.: Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease.Gut56(9) , 1319–1320 (2007).
  • Lane SJ , ArmJP, StaynovDZ, LeeTH et al.: Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma.Am. J. Respir. Cell Mol. Biol.11(1) , 42–48 (1994).
  • Raddatz D , BockemuhlM, RamadoriG: Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome.Eur. J. Gastroenterol. Hepatol.17(5) , 547–557 (2005).
  • Ishiguro Y : Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis.J. Gastroenterol.34(1) , 66–74 (1999).
  • Creed TJ , LeeRW, NewcombPV, di Mambro AJ, Raju M, Dayan CM: The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J. Immunol.183(1) , 164–171 (2009).
  • Walker KB , PotterJM, HouseAK: Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance.Clin. Exp. Immunol.68(1) , 162–167 (1987).
  • Lee RW , CreedTJ, SchewitzLP et al.: CD4+CD25(int) T cells in inflammatory diseases refractory to treatment with glucocorticoids.J. Immunol.179(11) , 7941–7948 (2007).
  • Goleva E , KisichKO, LeungDY: A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance.J. Immunol.169(10) , 5934–5940 (2002).
  • Adcock IM , LaneSJ, BrownCR, LeeTH, BarnesPJ: Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.J. Exp. Med.182(6) , 1951–1958 (1995).
  • Orii F , AshidaT, NomuraM et al.: Quantitative analysis for human glucocorticoid receptor α/β mRNA in IBD.Biochem. Biophys. Res. Commun.296(5) , 1286–1294 (2002).
  • Lane SJ , AdcockIM, RichardsD, HawrylowiczC, BarnesPJ, LeeTH: Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes.J. Clin. Invest.102(12) , 2156–2164 (1998).
  • Eklund BI , MobergM, BergquistJ, MannervikB et al.: Divergent activities of human glutathione transferases in the bioactivation of azathioprine.Mol. Pharmacol.70(2) , 747–754 (2006).
  • Kaplowitz N : Enzymatic thiolysis of azathioprine in vitro.Biochem. Pharmacol.25(21) , 2421–2426 (1976).
  • Watanabe A , HobaraN, NagashimaH: Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine.Acta Med. Okayama32(3) , 173–179 (1978).
  • De Miranda P , BeachamLM 3rd, Creagh TH, Elion GB: The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat. J. Pharmacol. Exp. Ther.187(3) , 588–601 (1973).
  • Kalra S , PaulMK, BalaramH, MukhopadhyayAK: Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase – an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine in ALL cell line.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.850(1–2) , 7–14 (2007).
  • Derijks LJ , GilissenLP, HooymansPM et al.: Review article: thiopurines in inflammatory bowel disease.Aliment. Pharmacol. Ther.24(5) , 715–729 (2006).
  • Gisbert JP , NiñoP, RodrigoL, CaraC, GuijarroLG: Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.Am. J. Gastroenterol.101 , 1–8 (2006).
  • Colombel JF , FerrariN, DebuysereH et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn‘s disease and severe myelosuppression during azathioprine therapy.Gastroenterology118(6) , 1025–1030 (2000).
  • Ujiie S , SasakiT, MizugakiM, IshikawaM, HiratsukaM: Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2–*24).Pharmacogenet. Genomics18(10) , 887–893 (2008).
  • Garat A , CauffiezC, RenaultN et al.: Characterisation of novel defective thiopurine S-methyltransferase allelic variants.Biochem. Pharmacol.76(3) , 404–415 (2008).
  • Kham SK , SohCK, AwDC, YeohAE: TPMT*26 (208F-->L), a novel mutation detected in a Chinese.Br. J. Clin. Pharmacol.68(1) , 120–123 (2009).
  • Salavaggione OE , WangL, WiepertM, YeeVC, WeinshilboumRM: Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics.Pharmacogenet. Genomics15(11) , 801–815 (2005).
  • Collie-Duguid ES , PritchardSC, PowrieRH et al.: The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.Pharmacogenetics9(1) , 37–42 (1999).
  • Kumagai K , HiyamaK, IshiokaS et al.: Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese.Pharmacogenetics11(3) , 275–278 (2001).
  • Evans WE : Comprehensive assessment of thiopurine S-methyltransferase (TPMT) alleles in three ethnic populations.J. Pediatr. Hematol. Oncol.24(5) , 335–336 (2002).
  • Gardiner SJ , GearryRB, BarclayML, BeggEJ: Two cases of thiopurine methyltransferase (TPMT) deficiency – a lucky save and a near miss with azathioprine.Br. J. Clin. Pharmacol.62(4) , 473–476 (2006).
  • Ansari A , HassanC, DuleyJ et al.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.Aliment. Pharmacol. Ther.16(10) , 1743–1750 (2002).
  • Bloomfeld RS , OnkenJE: Mercaptopurine metabolite results in clinical gastroenterology practice.Aliment. Pharmacol. Ther.17(1) , 69–73 (2003).
  • Kwan LY , DevlinSM, MirochaJM, PapadakisKA: Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.Dig. Liver Dis.40(6) , 425–432 (2008).
  • Dubinsky MC , YangH, HassardPV et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.Gastroenterology122(4) , 904–915 (2002).
  • Cuffari C , DassopoulosT, TurnboughL, ThompsonRE, BaylessTM: Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.Clin. Gastroenterol. Hepatol.2(5) , 410–417 (2004).
  • Sparrow MP , HandeSA, FriedmanS, CaoD, HanauerSB: Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.Clin. Gastroenterol. Hepatol.5(2) , 209–214 (2007).
  • Ansari A , ElliottT, BaburajanB et al.: Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.Aliment. Pharmacol. Ther.28(6) , 734–741 (2008).
  • Cao H , HegeleRA: DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency.J. Hum. Genet.47(11) , 620–622 (2002).
  • Marsh S , KingCR, AhluwaliaR, McLeodHL: Distribution of ITPA P32T alleles in multiple world populations.J. Hum. Genet.49(10) , 579–581 (2004).
  • De Ridder L , van Dieren JM, van Deventer HJ et al.: Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment. Pharmacol. Ther.23(8) , 1137–1141 (2006).
  • Breen DP , MarinakiAM, ArenasM, HayesPC: Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation.Liver Transpl.11(7) , 826–833 (2005).
  • Marinaki AM , AnsariA, DuleyJA et al.: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).Pharmacogenetics14(3) , 181–187 (2004).
  • von Ahsen N , ArmstrongVW, BehrensC et al.: Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study.Clin. Chem.51(12) , 2282–2288 (2005).
  • Gearry RB , RobertsRL, BarclayML, KennedyMA: Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine.Pharmacogenetics14(11) , 779–781 (2004).
  • van Dieren JM , van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ: ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut54(11) , 1664 (2005).
  • Hindorf U , LindqvistM, PetersonC et al.: Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.Gut55(10) , 1423–1431 (2006).
  • Brouwer C , MarinakiAM, LambooyLH, DuleyJA, Shobowale-BakreM, De Abreu RA: Pitfalls in the determination of mutant alleles of the thiopurine methyltransferase gene. Leukemia15(11) , 1792–1793 (2001).
  • Duley JA , MarinakiAM, ArenasM, FlorinTH: Do ITPA and TPMT genotypes predict the development of side effects to AZA?.Gut55(7) , 1048–1049 (2006).
  • Zelinkova Z , DerijksLJ, StokkersPC et al.: Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.Clin. Gastroenterol. Hepatol.4(1) , 44–49 (2006).
  • Hawwa AF , MillershipJS, CollierPS et al.: Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.Br. J. Clin. Pharmacol.66(4) , 517–528 (2008).
  • Allorge D , HamdanR, BrolyF, LibersaC, ColombelJF: ITPA genotyping test does not improve detection of Crohn‘s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression.Gut54(4) , 565 (2005).
  • Kurzawski M , DziewanowskiK, LenerA, DrozdzikM: TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients.Eur. J. Clin. Pharmacol.65(5) , 533–540 (2009).
  • Uchiyama K , NakamuraM, KubotaT, YamaneT, FujiseK, TajiriH: Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment.J. Gastroenterol.44(3) , 197–203 (2009).
  • Stocco G , CheokMH, CrewsKR et al.: Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.Clin. Pharmacol. Ther.85(2) , 164–172 (2009).
  • Bierau J , LindhoutM, BakkerJA: Pharmacogenetic significance of inosine triphosphatase.Pharmacogenomics8(9) , 1221–1228 (2007).
  • Rashidi MR , BeedhamC, SmithJS, DavaranS: In vitro study of 6-mercaptopurine oxidation catalysed by aldehyde oxidase and xanthine oxidase.Drug Metab. Pharmacokinet.22(4) , 299–306 (2007).
  • Al Hadithy AF , de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR: Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig. Liver Dis.37(4) , 282–297 (2005).
  • Ansari A , AslamZ, de Sica A et al.: Influence of xanthine oxidase on thiopurine metabolism in Crohn‘s disease. Aliment. Pharmacol. Ther.28(6) , 749–757 (2008).
  • Relling MV , LinJS, AyersGD, EvansWE: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.Clin. Pharmacol. Ther.52(6) , 643–658 (1992).
  • Guerciolini R , SzumlanskiC, WeinshilboumRM: Human liver xanthine oxidase: nature and extent of individual variation.Clin. Pharmacol. Ther.50(6) , 663–672 (1991).
  • Yamaguchi Y , MatsumuraT, IchidaK, OkamotoK, NishinoT: Human xanthine oxidase changes its substrate specificity to aldehyde oxidase type upon mutation of amino acid residues in the active site: roles of active site residues in binding and activation of purine substrate.J. Biochem. (Tokyo)141(4) , 513–524 (2007).
  • Kudo M , MotekiT, SasakiT et al.: Functional characterization of human xanthine oxidase allelic variants.Pharmacogenet. Genomics18(3) , 243–251 (2008).
  • Zimm S , CollinsJM, O‘NeillD, ChabnerBA, PoplackDG: Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol.Clin. Pharmacol. Ther.34(6) , 810–817 (1983).
  • Harrison R : Structure and function of xanthine oxidoreductase: where are we now?.Free Radic. Biol. Med.33(6) , 774–797 (2002).
  • Smith MA , MarinakiAM, ArenasM et al.: Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease.Aliment. Pharmacol. Ther.30(4) , 375–384 (2009).
  • Kitamura S , SugiharaK, OhtaS: Drug-metabolizing ability of molybdenum hydroxylases.Drug Metab. Pharmacokinet.21(2) , 83–98 (2006).
  • Keuzenkamp-Jansen CW , van Baal JM, de Abreu RA, de Jong JG, Zuiderent R, Trijbels JM: Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration. Clin. Chem.42(3) , 380–386 (1996).
  • Al-Salmy HS : Individual variation in hepatic aldehyde oxidase activity.IUBMB Life51(4) , 249–253 (2001).
  • Sugihara K , KitamuraS, TatsumiK, AsaharaT, DohiK: Differences in aldehyde oxidase activity in cytosolic preparations of human and monkey liver.Biochem. Mol. Biol. Int.41(6) , 1153–1160 (1997).
  • Schwarz G : Molybdenum cofactor biosynthesis and deficiency.Cell Mol. Life Sci.62(23) , 2792–2810 (2005).
  • Per H , GümüşH, IchidaK, CağlayanO, KumandaşS: Molybdenum cofactor deficiency: clinical features in a Turkish patient.Brain Dev.29(6) , 365–368 (2007).
  • Peretz H , NaamatiMS, LevartovskyD et al.: Identification and characterization of the first mutation (Arg776Cys) in the C-terminal domain of the human molybdenum cofactor sulfurase (HMCS) associated with type II classical xanthinuria.Mol. Genet. Metab.91(1) , 23–29 (2007).
  • Haglund S , TaipalensuuJ, PetersonC, AlmerS: IMPDH activity in thiopurine-treated patients with inflammatory bowel disease – relation to TPMT activity and metabolite concentrations.Br. J. Clin. Pharmacol.65(1) , 69–77 (2007).
  • Roberts RL , GearryRB, BarclayML, KennedyMA: IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.Pharmacogenomics J.7 , 312–317 (2006).
  • Rosman M , LeeMH, CreaseyWA, SartorelliAC: Mechanisms of resistance to 6-thiopurines in human leukemia.Cancer Res.34(8) , 1952–1956 (1974).
  • Rosman M , WilliamsHE: Leukocyte purine phosphoribosyltransferases in human leukemias sensitive and resistant to 6-thiopurines.Cancer Res.33(6) , 1202–1209 (1973).
  • Hobara N , WatanabeA: Impaired metabolism of azathioprine in carbon tetrachloride-injured rats.Hepatogastroenterology28(4) , 192–194 (1981).
  • Kaplowitz N : Interaction of azathioprine and glutathione in the liver of the rat.J. Pharmacol. Exp. Ther.200(3) , 479–486 (1977).
  • Rahman SH , IbrahimK, LarvinM, KingsnorthA, McMahonMJ: Association of antioxidant enzyme gene polymorphisms and glutathione status with severe acute pancreatitis.Gastroenterology126(5) , 1312–1322 (2004).
  • Townsend DM , TewKD, TapieroH: The importance of glutathione in human disease.Biomed. Pharmacother.57(3–4) , 145–155 (2003).
  • Lee AU , FarrellGC: Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury.J. Hepatol.35(6) , 756–764 (2001).
  • Menor C , Fernandez-MorenoMD, FueyoJA et al.: Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine.J. Pharmacol. Exp. Ther.311(2) , 668–676 (2004).
  • Stocco G , MartelossiS, BarabinoA et al.: Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.Inflamm. Bowel Dis.13(1) , 57–64 (2007).
  • Rahman SH , NannyC, IbrahimK et al.: Genetic polymorphisms of GSTT1, GSTM1, GSTP1, MnSOD, and catalase in nonhereditary chronic pancreatitis: evidence of xenobiotic stress and impaired antioxidant capacity.Dig. Dis. Sci.50(7) , 1376–1383 (2005).
  • Pieters R , VeermanAJ: The role of 5‘nucleotidase in therapy-resistance of childhood leukemia.Med. Hypotheses27(1) , 77–80 (1988).
  • Kerstens PJ , StolkJN, BoerboomsAM et al.: Purine enzymes in rheumatoid arthritis: possible association with response to azathioprine. A pilot study.Ann. Rheum. Dis.53(9) , 608–611 (1994).
  • Kerstens PJ , StolkJN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA: Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum.38(1) , 142–145 (1995).
  • Kerstens PJ , StolkJN, HilbrandsLB, van de Putte LB, De Abreu RA, Boerbooms AM: 5-nucleotidase and azathioprine-related bone-marrow toxicity. Lancet342(8881) , 1245–1246 (1993).
  • Baburajan B , PrescottN, HudspithB et al.: A functional study of the effect of the 14bp insertion deletion polymorphism of the HLA-G gene on response to immunomodulatory therapy in inflammatory bowel disease.Gut58(Suppl. 1) , A24 (2009).
  • Baburajan B , PrescottN, HerrlingerK et al.: HLA-G 14bp insertion-deletion polymorphism influences response to methotrexate in inflammatory bowel disease.Gut56(Suppl. 11) , A107 (2007).
  • Rizzo R , RubiniM, GovoniM et al.: HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis.Pharmacogenet. Genomics16(9) , 615–623 (2006).
  • Szakacs G , PatersonJK, LudwigJA et al.: Targeting multidrug resistance in cancer.Nat. Rev. Drug Discov.5(3) , 219–234 (2006).
  • van der Kolk DM , de Vries EG, Müller M, Vellenga E: The role of drug efflux pumps in acute myeloid leukemia. Leuk. Lymphoma43(4) , 685–701 (2002).
  • Chen ZS , LeeK, KruhGD: Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine.J. Biol. Chem.276(36) , 33747–33754 (2001).
  • Wijnholds J , MolCA, van Deemter L et al.: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl Acad. Sci. USA97(13) , 7476–7481 (2000).
  • Borst P , ElferinkRO: Mammalian ABC transporters in health and disease.Annu. Rev. Biochem.71 , 537–592 (2002).
  • Wielinga PR , ReidG, ChallaEE et al.: Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.Mol. Pharmacol.62(6) , 1321–1331 (2002).
  • Szakacs G , AnnereauJP, LababidiS et al.: Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.Cancer Cell6(2) , 129–137 (2004).
  • Krishnamurthy P , SchwabM, TakenakaK et al.: Transporter-mediated protection against thiopurine-induced hematopoietic toxicity.Cancer Res.68(13) , 4983–4989 (2008).
  • Herrlinger KR , JewellDP: Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.Aliment Pharmacol. Ther.24(10) , 1403–1412 (2006).
  • Rots MG , PietersR, PetersGJ et al.: Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.Blood93(5) , 1677–1683 (1999).
  • Herrlinger KR , CummingsJR, BarnardoMC, SchwabM, AhmadT, JewellDP: The pharmacogenetics of methotrexate in inflammatory bowel disease.Pharmacogenet. Genomics15(10) , 705–711 (2005).
  • Cheng Q , WuB, KagerL et al.: A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.Pharmacogenetics14(8) , 557–567 (2004).
  • Laverdière C , ChiassonS, CosteaI, MoghrabiA, KrajinovicM: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.Blood100(10) , 3832–3834 (2002).
  • Wessels JA , de Vries-Bouwstra JK, Heijmans BT et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum.54(4) , 1087–1095 (2006).
  • Baburajan B , ArenasM, PrescottN et al.: The pharmacogenetics of folate and purine metabolic pathways in methotrexate therapy of inflammatory bowel disease.Gut56(Suppl. 11) , A106 (2007).
  • Dervieux T , KremerJ, LeinDO et al.: Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.Pharmacogenetics14(11) , 733–739 (2004).
  • Wessels JA , van der Kooij SM, le Cessie S et al.: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum.56(6) , 1765–1775 (2007).
  • Zhang H , MasseyD, TremellingM, ParkesM: Genetics of inflammatory bowel disease: clues to pathogenesis.Br. Med. Bull.87 , 17–30 (2008).
  • Mascheretti S , HampeJ, CroucherPJ et al.: Response to infliximab treatment in Crohn‘s disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials.Pharmacogenetics12(7) , 509–515 (2002).
  • Vermeire S , LouisE, RutgeertsP et al.: NOD2/CARD15 does not influence response to infliximab in Crohn‘s disease.Gastroenterology123(1) , 106–111 (2002).
  • Weiss B , LebowitzO, FidderHH et al.: Response to medical treatment in patients with Crohn‘s disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis.Dig. Dis. Sci. (2009) (Epub ahead of print).
  • Urcelay E , MendozaJL, MartinezA et al.: IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.World J. Gastroenterol.11(8) , 1187–1192 (2005).
  • Mascheretti S , HampeJ, KuhbacherT et al.: Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn‘s disease treated with infliximab.Pharmacogenomics J.2(2) , 127–136 (2002).
  • Pierik M , VermeireS, SteenKV et al.: Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.Aliment. Pharmacol. Ther.20(3) , 303–310 (2004).
  • Matsukura H , IkedaS, YoshimuraN, TakazoeM, MuramatsuM: Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn‘s disease.Aliment. Pharmacol. Ther.27(9) , 765–770 (2008).
  • Dideberg V , TheatreE, FarnirF et al.: The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn‘s disease.Pharmacogenet. Genomics16(10) , 727–734 (2006).
  • Taylor KD , PlevySE, YangH et al.: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn‘s disease.Gastroenterology120(6) , 1347–1355 (2001).
  • Dideberg V , LouisE, FarnirF et al.: Lymphotoxin α gene in Crohn’s disease patients: absence of implication in the response to infliximab in a large cohort study.Pharmacogenet. Genomics16(5) , 369–373 (2006).
  • Ozeki T , FuruyaY, NaganoC et al.: Analysis of linkage between lymphotoxin a haplotype and polymorphisms in 5‘-flanking region of tumor necrosis factor α gene associated with efficacy of infliximab for Crohn’s disease patients.Mutat. Res.602(1–2) , 170–174 (2006).
  • Cartron G , DacheuxL, SallesG et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene.Blood99(3) , 754–758 (2002).
  • Louis E , El Ghoul Z, Vermeire S et al.: Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn‘s disease. Aliment. Pharmacol. Ther.19(5) , 511–519 (2004).
  • Louis EJ , WatierHE, SchreiberS et al.: Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn‘s disease: a subanalysis of the ACCENT I study.Pharmacogenet. Genomics16(12) , 911–914 (2006).
  • Willot S , VermeireS, OhresserM et al.: No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn‘s disease.Pharmacogenet. Genomics16(1) , 37–42 (2006).
  • Hlavaty T , PierikM, HenckaertsL et al.: Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn‘s disease.Aliment. Pharmacol. Ther.22(7) , 613–626 (2005).
  • Hlavaty T , FerranteM, HenckaertsL, PierikM, RutgeertsP, VermeireS: Predictive model for the outcome of infliximab therapy in Crohn‘s disease based on apoptotic pharmacogenetic index and clinical predictors.Inflamm. Bowel Dis.13(4) , 372–379 (2007).
  • Magdelaine-Beuzelin C , VermeireS, GoodallM et al.: IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.Pharmacogenet. Genomics19(5) , 383–387 (2009).
  • Arijs I , LiK, ToedterG et al.: Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.Gut58(12) , 1612–1619 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.